Rho-kinase inhibitors are indicated treatments for cerebral vasospasm and glaucoma,16,46 and have emerging potential for use in other vascular conditions (e.g. erectile dysfunction, migraine)47,48 and chronic airway disease.49 Our novel findings suggest that RhoA/Rho-kinase signalling is a therapeutic target in patients with cardiovascular symptoms post-COVID-19. This evidence concerns the gene RHOA and glaucoma.